Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Design Therapeutics Inc shares valued at $2,851,050 were purchased by Logos Global Master Fund LP on Nov 07 ’25. At $6.87 per share, Logos Global Master Fund LP acquired 415,000 shares.
Also, William Arsani sold 562,627 shares, netting a total of over 2,953,792 in proceeds. Following the sale of shares at $5.25 each, the insider now holds 1,000,000 shares.
Before that, Logos Opportunities Fund II LP had added 217,627 shares to its account. In a trade valued at $1,083,783, the Director bought Design Therapeutics Inc shares for $4.98 each.
As published in a research note from Piper Sandler on May 07, 2024, Design Therapeutics Inc [DSGN] has been rated up from a Neutral to an Overweight and the price target has been revised to $12 from $6. Analysts at Piper Sandler downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid November. As of August 15, 2023, Wedbush has decreased its “an Outperform” rating to a “Neutral” for DSGN. Earlier on August 15, 2023, SVB Securities downgraded its rating. Their new recommendation was “a Market perform” for DSGN stock which previously was a “an Outperform”.
Analyzing DSGN Stock Performance
On last trading session, Design Therapeutics Inc [NASDAQ: DSGN] plunged -1.93% to $7.61. The stock’s lowest price that day was $7.455, but it reached a high of $7.925 in the same session. During the last five days, there has been a surge of approximately 16.18%. Over the course of the year, Design Therapeutics Inc shares have jumped approximately 30.53%. Shares of the company reached a 52-week high of $7.93 on 11/07/25 and a 52-week low of $2.60 on 04/11/25.
Support And Resistance Levels for Design Therapeutics Inc (DSGN)
According to the 24-hour chart, there is a support level at 7.40, which, if violated, would cause prices to drop to 7.19. In the upper region, resistance lies at 7.87. The next price resistance is at 8.14. RSI (Relative Strength Index) is 62.40 on the 14-day chart, showing neutral technical sentiment.
Is Design Therapeutics Inc subject to short interest?
Stocks of Design Therapeutics Inc saw a sharp steep in short interest on 2025-10-31 dropping by -1.7 million shares to 1.85 million. Data from Yahoo Finance shows that the short interest on 2025-09-30 was 3.55 million shares. A decline of -92.02% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.64 of the overall float, the days-to-cover ratio (short ratio) decline to 9.64.
Which companies own the most shares of Design Therapeutics Inc (DSGN)?
In terms of Design Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 10 in the next 12 months, up nearly 28.87% from the previous closing price of $7.76. Analysts anticipate Design Therapeutics Inc stock to reach 12 by 2025, with the lowest price target being 7. In spite of this, 2 analysts ranked Design Therapeutics Inc stock as Buy at the end of 2025. On August 15, 2023, RBC Capital Mkts assigned a price target of “a Sector perform” to the stock and downgraded coverage with a $7.
